Summit Therapeutics SMMT Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's return on invested capital?
- Summit Therapeutics (SMMT) reported return on invested capital of -81.8% in Q4 2024.
- How has Summit Therapeutics's return on invested capital changed year-over-year?
- Summit Therapeutics's return on invested capital increased by 50.6% year-over-year, from -165.6% to -81.8%.
- What is the long-term trend for Summit Therapeutics's return on invested capital?
- Over 4 years (2020 to 2024), Summit Therapeutics's return on invested capital has grown at a -31.0% compound annual growth rate (CAGR), from -361.7% to -81.8%.
- What does return on invested capital mean?
- The after-tax return the business earns on all the capital — debt and equity — invested in it.
- How do you interpret return on invested capital?
- The cleanest measure of business quality: ROIC sustained above the cost of capital creates value, below it destroys value. Compare against WACC, not against zero.
- How does return on invested capital compare across companies?
- Highly comparable across companies as a quality screen. Sector-sensitive definitions of invested capital mean banks/insurers are best excluded.